- Home
- RPAY vs OBIO Comparison
RPAY vs OBIO Comparison
Compare RPAY & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | OBIO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 237.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RPAY | OBIO |
|---|---|---|
| Price | $3.03 | $3.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $6.81 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 958.3K | 190.5K |
| Earning Date | 02-27-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,947,000.00 | $2,818,000.00 |
| Revenue This Year | $0.22 | $36.66 |
| Revenue Next Year | $6.91 | $2.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $2.80 | $2.20 |
| 52 Week High | $7.57 | $5.98 |
Technical Indicators
Market Signals| Indicator | RPAY | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 31.03 | 44.90 |
| Support Level | $3.30 | $3.62 |
| Resistance Level | $3.40 | $4.22 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 29.49 | 47.13 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.